Gemphire Therapeutics (GEMP) Given News Sentiment Rating of 0.06

Media stories about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a news impact score of 0.06 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.3298822917399 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of GEMP traded down $0.06 during mid-day trading on Monday, reaching $1.38. The company had a trading volume of 388,600 shares, compared to its average volume of 396,682. The company has a quick ratio of 4.64, a current ratio of 4.64 and a debt-to-equity ratio of 0.50. Gemphire Therapeutics has a 52 week low of $0.83 and a 52 week high of $11.43. The stock has a market cap of $20.54 million, a P/E ratio of -0.43 and a beta of 2.91.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Monday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. equities analysts anticipate that Gemphire Therapeutics will post -1.99 EPS for the current year.

A number of brokerages have recently commented on GEMP. Zacks Investment Research cut Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Canaccord Genuity reissued a “buy” rating and issued a $6.00 price target on shares of Gemphire Therapeutics in a research report on Monday, August 13th. Jefferies Financial Group cut Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Monday, August 13th. Roth Capital reissued a “neutral” rating and issued a $30.00 price target on shares of Gemphire Therapeutics in a research report on Friday, August 10th. Finally, Raymond James cut Gemphire Therapeutics from an “outperform” rating to a “market perform” rating and set a $22.00 price target on the stock. in a research report on Tuesday, August 7th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Gemphire Therapeutics currently has an average rating of “Hold” and an average target price of $17.82.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Read More: Understanding Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply